PP01.01 Evolving Survival Outcomes In Pulmonary Sarcomatoid Cancer in the era of Immunotherapy

PP01.02 Genomic and Clinical Heterogeneity of Patients with Non-Small Cell Lung Cancer Tumors Harboring PIK3CA Mutations

PP01.03 Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with oncogene-driver negative NSCLC who have never smoked

PP01.04 Clinical Outcomes of ALK Tyrosine Kinase Inhibitor Therapy in Patients with ALK Testing Discordance by Immunohistochemistry and Next-Generation Sequencing

PP01.06 Real-World Treatment Patterns and Outcomes of Tyrosine Kinase Inhibitors (TKI) in Anaplastic Lymphoma Kinase Positive (ALK+) Metastatic Non-Small Cell Lung Cancer (NSCLC)

PP01.08 Retrospective Analysis of Treatment Outcomes for T-DM1 (Trastuzumab Emtansine) following T-DXd (Trastuzumab Deruxtecan) and T-DXd following T-DM1 in HER2-Mutated Non-Small Cell Lung Cancer

PP01.10 Outcomes after Radiation Therapy for Oligoprogressive Disease in Patients with EGFR-mutant Metastatic Non-Small Cell Lung Cancer on Osimertinib

PP01.11 Clinicopathologic features of patients with advanced non-small cell lung cancer (NSCLC) and exceptional response to immunotherapy

PP01.12 Characterizing PET-CT Avidity and Immune Checkpoint Inhibitor-Related Pulmonary Adverse Events in NSCLC Patients

PP01.13 Presenting features and diagnostic delays of NUT carcinoma: A report from the NUT carcinoma registry

PP01.14 Body Composition in Advanced Non-Small Cell Lung Cancer treated with Immunotherapy

PP01.15 Risk factors and outcomes for myocarditis in patients with lung cancer receiving immune checkpoint inhibitor: a global real-world analysis

PP01.16 Racial Disparities in the Outcome of EGFRm NSCLC Patients

PP01.17 Real-world experience of amivantamab monotherapy in EGFR mutated non-small cell lung cancer

PP01.19 Real-World Outcomes with Tarlatamab in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

PP01.21 Serum Tumor Markers in Metastatic Oncogene-Driven Lung Adenocarcinoma

PP01.22 Outcomes of EGFR-mutant squamous cell non-small cell lung cancers with amivantamab plus lazertinib

PP01.24 Clinical Characteristics and Outcomes of Patients with Germline EGFR Mutations: A Single Institution Experience

PP01.25 Real-world demographics, clinical characteristics, and overall survival (OS) among Canadian patients (pts) with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line osimertinib (CARMA-BROStudy; NCT04151342)

PP01.26 Real-world patterns of care post-first line osimertinib (osi) in Canadian EGFR-mutated patients (pts) with non-small cell lung cancer (NSCLC): implications for targeted therapy + chemo regimens in the post-osi setting

PP01.27 Evaluating the clinical impact of RBM10 mutations in non-small-cell lung cancer

PP01.28 Multiplex immunofluorescence analysis of tumor microenvironment improves prediction of immunotherapy efficacy in NSCLC.

PP01.29 Nectin-4 Overexpression in ERBB2 Non-Small Cell Lung Cancer: A Multi-Center Study

PP01.30 Predictors of poor progression-free survival among Canadian patients with advanced EGFR-mutated non-small cell lung cancer treated with first-line osimertinib in a real-world setting

PP01.31 Decoding First-line strategies in EGFR-mutated NSCLC: A Computational Analysis of FLAURA2 vs. MARIPOSA

PP01.33 Pulse-dose osimertinib for treatment of leptomeningeal disease or refractory brain metastases in EGFR-mutated non-small cell lung cancer

PP01.36 Clinicogenomic Analysis of EGFR-mutant Lung Cancers Identifies Rb and AKT Pathway Alterations as Hallmarks of Squamous Transformation

PP01.37 The landscape of PIK3CA alterations in lung cancer

PP01.38 High Frequency of Actionable Driver Alterations in Lung Cancer Patients with Germline MUTYH Mutations: A Retrospective Analysis

PP01.39 Elucidating the Role of ISL1 as a Predictive Biomarker for Lurbinectedin Response in Small Cell Lung Cancer

PP01.40 Wild Type TP53 is Associated with Therapeutic Activity of Nuclear Export Inhibition in KRAS Mutant Non-Small Cell Lung Cancer

PP01.41 Real-World Intracranial and Extracranial Efficacy Plus Safety Analysis of Tarlatamab in Extensive-Stage Small Cell Lung Cancer

PP01.42 A Single-Center Experience Initiating Tarlatamab Treatment for Relapsed Extensive-Stage Small Cell Lung Cancer: Navigating Cytokine Release Syndrome

PP01.43 Overlap of DLL3 and SEZ6 Expression in High-Grade Neuroendocrine Carcinomas

PP01.44 Real-World Risk Factors for ALK-Inhibitor Associated Weight Gain in Non-Small Cell Lung Cancer

PP01.46 Clinical outcomes of stage IV lung invasive mucinous adenocarcinoma in the era of immunotherapy: a SEER database analysis

PP01.48 Contemporary analysis of adjuvant treatment patterns in patients with resected NSCLC in the US

PP01.49 Neoadjuvant PD-1 blockade in combination with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer

PP01.51 ERBB3-BCAR4 is a recurrent fusion in lung adenocarcinoma cases that lack other driver alterations

PP01.52 Incidence, Patterns, and Clinical Outcomes of Brain Metastases in Young Adults with KRAS-altered Non-Small Cell Lung Cancer

PP01.54 High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Datasets

PP01.55 Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry